Osmotica Pharmaceuticals, a leading osmotic drug delivery company, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The Bridgewater, NJ-based company was founded in 1986 and booked $262 million in sales for the 12 months ended June 30, 2018. It plans to list on the Nasdaq under the symbol OSMT. Osmotica Pharmaceuticals filed confidentially on May 9, 2018. Jefferies, Barclays and RBC Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
